Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022;11(3):260-272.
doi: 10.22088/IJMCM.BUMS.11.3.260.

Current Perspectives and Future Prospects of mRNA Vaccines against Viral Diseases: A Brief Review

Vasavi Koppu  1 , Deepa Poloju  1 , Bhavani Puvvala  1 , Kavitha Madineni  1 , Shilpa Balaji  1 , Chandana Muraleedharan Pillai Sheela  1 , Sri Sai Charan Manchikanti  1 , Satpathy Moon Moon  1
Affiliations
Review

Current Perspectives and Future Prospects of mRNA Vaccines against Viral Diseases: A Brief Review

Vasavi Koppu et al. Int J Mol Cell Med. 2022.

Abstract

The mRNA vaccines replace our conventional vaccines (live-attenuated and inactivated vaccines) due to their high safety, efficacy, potency and low cost for their manufacturing. Since these many years, the use of these mRNA vaccines has been restricted as they are unstable and their low efficiency in in-vivo delivery. But now, these problems have been solved by recent technological advances. Many studies conducted in animal models and humans demonstrated the good results for the mRNA vaccines. This review provides you a detailed overview of mRNA viral vaccines and considers the current perspectives and future prospects.

Keywords: codon optimization; lipid nanoparticle; mRNA; vaccine; virus.

PubMed Disclaimer

Figures

Fig.1
Fig.1
Self-amplifying mRNA construct
Fig.2
Fig.2
Strategies for optimizing mRNA pharmacology
Fig.3
Fig.3
Mechanism of action of mRNA vaccines
Fig.4
Fig.4
Delivery systems of mRNA vaccines
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Xu S, Yang K, Li R, et al. mRNA Vaccine Era-Mechanisms, Drug Platform and Clinical Prospection. Int J Mol Sci. 2020:21. - PMC - PubMed
    1. Versteeg L, Almutairi MM, Hotez PJ, et al. Enlisting the mRNA Vaccine Platform to Combat Parasitic Infections. Vaccines (Basel) 2019:7. - PMC - PubMed
    1. Stitz L, Vogel A, Schnee M, et al. A thermostable messenger RNA based vaccine against rabies. PLoS Negl Trop Dis. 2017;11:e0006108. - PMC - PubMed
    1. Jackson NAC, Kester KE, Casimiro D, et al. The promise of mRNA vaccines: a biotech and industrial perspective. NPJ Vaccines. 2020;5:11. - PMC - PubMed
    1. Batty CJ, Heise MT, Bachelder EM, et al. Vaccine formulations in clinical development for the prevention of severe acute respiratory syndrome coronavirus 2 infection. Adv Drug Deliv Rev. 2021;169:168–89. - PMC - PubMed

LinkOut - more resources